GM-CSF–dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia-Reference-Cited by-同舟云学术

GM-CSF–dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia

Published:2013-06-20 Issue:25 Volume:121 Page:5068-5077
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Padron Eric¹,Painter Jeffrey S.²,Kunigal Sateesh¹,Mailloux Adam W.²,McGraw Kathy²,McDaniel Jessica M.²,Kim Eunhee³,Bebbington Christopher⁴,Baer Mark⁴,Yarranton Geoffrey⁴,Lancet Jeffrey¹,Komrokji Rami S.¹,Abdel-Wahab Omar³,List Alan F.¹,Epling-Burnette Pearlie K.²⁵

Affiliation:

1. Department of Hematologic Malignancies, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;

2. Immunology Program, H. Lee Moffitt Cancer Center and the University of South Florida, Tampa, FL;

3. Human Oncology and Pathogenesis Program and Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY;

4. KaloBios Pharmaceuticals, Inc., South San Francisco, CA; and

5. James A. Haley VA Hospital, Tampa, FL

Abstract

Key Points GM-CSF–dependent STAT5 hypersensitivity is detected in 90% of CMML samples and is enhanced by signaling mutations. Treatment with a GM-CSF–neutralizing antibody and JAK2 inhibitors reveals therapeutic potential.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/121/25/5068/1366682/5068.pdf

Reference38 articles.

1. Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia.;Emanuel;Leukemia,2008

2. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs.;Rollison;Blood,2008

3. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.;Jankowska;Blood,2011

4. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.;Kohlmann;J Clin Oncol,2010

5. A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia.;Klinakis;Nature,2011

Cited by 139 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predicting which subsets of patients with myelodysplastic neoplasms are more likely to progress to overt chronic myelomonocytic leukemia;Leukemia & Lymphoma;2024-07-14

2. Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPN;Leukemia Research;2024-07

3. CXCL8 secreted by immature granulocytes inhibits wildtype hematopoiesis in chronic myelomonocytic leukemia;2024-03-13

4. Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management;American Journal of Hematology;2024-03-07

5. Myeloproliferative Neoplasms: Contemporary Review and Molecular Landscape;International Journal of Molecular Sciences;2023-12-12